Compare Fidelity National Information Servcs Inc (FIS) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs Recursion Pharmaceuticals Inc — how do they compare? Fidelity National Information Servcs Inc trades at $42.67 (market cap $21.92B), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.78B). The key difference: Fidelity National Information Servcs Inc is far larger — about 12.3× Recursion Pharmaceuticals Inc's market cap, and Fidelity National Information Servcs Inc pays a 4.14% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| FIS | RXRX | |
|---|---|---|
Market Cap | $21.92B | $1.78B |
Sector | Technology | Health |
52-Week High | $72.77 | $6.79 |
52-Week Low | $37.72 | $2.84 |
Enterprise Value | $42.43B | $1.30B |
Dividend Yield | 4.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $42.77, down slightly on the day, with a bearish technical signal. The company reported Q2 2026 earnings of $1.48 per share, beating estimates, driven by Banking Solutions growth. Recent news highlights the global expansion of its Digital One Commercial platform into the APAC region. Valuation metrics appear attractive with a P/E of 6.57 and a consensus price target of $50.20, though the company lowered its full-year Capital Markets outlook.
The outlook is mixed; strong fundamentals and analyst support suggest upside potential, but near-term price action is weak and execution risks in the Capital Markets segment pose a challenge. The stock offers value but requires monitoring of the revised guidance and competitive pressures in the fintech space.
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
